Symptoms
By Mayo Clinic staffSigns and symptoms of breast cancer may include:
- A breast lump or thickening that feels different from the surrounding tissue
- Bloody discharge from the nipple
- Change in the size or shape of a breast
- Changes to the skin over the breast, such as dimpling
- Inverted nipple
- Peeling, scaling or flaking of the nipple or breast skin
- Redness or pitting of the skin over your breast, like the skin of an orange
When to see a doctor
Although the majority of breast changes don't turn out to be cancer, make an appointment to see your doctor if you find a lump or other change in your breast. Even if you've just had a mammogram with normal results, it's still important to have your doctor evaluate any changes.
- Breast cancer. American Cancer Society. http://www.cancer.org/acs/groups/cid/documents/webcontent/003090-pdf.pdf. Accessed March 17, 2011.
- What you need to know about breast cancer. National Cancer Institute. http://www.cancer.gov/cancertopics/wyntk/breast/AllPages/Print. Accessed March 19, 2011.
- Chlewbowski RT, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. Journal of the American Medical Association. 2010;304:1684.
- Giuliano AE, et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis. Journal of the American Medical Association. 2011;305:569.
- Van Wely BJ, et al. Systematic review of the effect of external beam radiation therapy to the breast on axillary recurrence after negative sentinel lymph node biopsy. British Journal of Surgery. 2011;98:326.
- Robert NJ, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. Journal of Clinical Oncology. In Press. Accessed March 22, 2011.
- Burstein HJ. Bevacizumab for advanced breast cancer: All tied up with a RIBBON? Journal of Clinical Oncology. In Press. Accessed March 22, 2011.
- Choueiri TK, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. Journal of Clinical Oncology. 2011;29:632.
- Petrelli F, et al. Bevacizumab in advanced breast cancer: An opportunity as second-line therapy? Medical Oncology. In Press. Accessed March 22, 2011.
- Gnant M, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. The New England Journal of Medicine. 2009;360:679.
- Coleman R, et al. Zoledronic acid use in cancer patients. Cancer. 2011;117:11.
- Pruthi S (expert opinion). Mayo Clinic, Rochester, Minn. March 22, 2011.
- Unexpected AZURE results lead to rethink for Zometa. Expert Review of Anticancer Therapy. 2011;11:329.
- Moynihan TJ (expert opinion). Mayo Clinic, Rochester, Minn. April 3, 2011.
- FDA commissioner removes breast cancer indication from Avastin label. Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/ucm279485.htm. Accessed Nov. 18, 2011.


Find Mayo Clinic on